Boehringer Ingelheim start EGFR targeted drugs BI II clinical trial of 1,482,694

Recently, Boehringer Ingelheim announced that will start its third representative of epidermal growth factor receptor (EGFR) targeted drug BI 1482694 (HM61713) Phase II clinical trial to evaluate its mutant gene in the EGFR -T790M positive non-small cell lung cancer (NSCLC) in efficacy and safety.
Professor Keunchil Par from Sungkyunkwan University, Samsung Medical Center Hematology and Oncology, currently serve as the coordinating investigator of the clinical trial, he said: the third-generation EGFR-targeting drugs, primarily to overcome the T790M mutation caused first and second generation drugs resistant lung cancer for the T790M mutation positive people to provide a better treatment plan, avoid taking other more serious side effects of chemotherapy drugs brought.
HM61713 is a new and irreversible EGFR mutation-specific tyrosine kinase inhibitors (EGFR TKIs), mainly for the T790M mutation positive patients with lung cancer, "tailored." In American Society of Clinical Oncology (ASCO) annual meeting, held this year, Boehringer Ingelheim posted HM61713 of Phase I / II clinical trial interim results show that the drug has a strong efficacy and safety profile in the study population.
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) for the treatment of advanced non-small cell lung cancer (NSCLC), in recent years more and more attention. The acceptance of EGFR-TKI therapy in NSCLC patients, more than half the body's resistance to the possibility there will be, the main mechanism of this acquired resistance to EGFR-T790M mutation is. Currently T790M mutation gene targets for drugs list is still a blank, if HM61713 stand out, no doubt will be able to meet the strong market demand for drugs, the market potential should not be overlooked.
In recent years, Boehringer EGFR mutations in lung cancer treatment has been in a leadership position, FDA approved Giotrif / Gilotrif (AFATINIB) in 2013 for the EGFR mutation (del19 deletion) type metastatic non-small cell lung cancer ( NSCLC) patients. Boehringer said that for 2017 to obtain a marketing authorization HM61713, if successfully approved, its product line to conquer the EGFR lung cancer market will become more.
MehdiShahidi medical director Dr. Boehringer solid tumors, commented: "We carried out a number of tumor-depth cooperation community, we devoted a lot of research and development funds and energy to lung cancer product line, with a view to more lung cancer patients to provide more appropriate treatment The first start pivotal clinical trials .HM61713 will become more late Phase III clinical trial evaluating an important milestone. "